Alteration of Deep Brain Stimulation Parameters for Dystonia

Status Recruiting

Clinical Trial Summary

Deep brain stimulation (DBS) involves placing electrodes into the brain. Through these electrodes, artificial electrical signals are chronically delivered into deep brain regions in order to alter abnormal brain activity. The artificial electrical signals are generated by a battery that is inserted under the skin of the chest. DBS is used to treat several disorders of movement, including dystonia. In dystonia, the electrodes are inserted into a brain region called the globus pallidus.

Globus pallidus stimulation can be very effective therapy for dystonia. However not all patients are equally responsive and therapeutic outcomes can be frustratingly variable. The reason for this variability is unclear. Such variability in response may need to be met by tailoring stimulation to individual patients.

Another issue with deep brain stimulation is battery life. Eventually, batteries become depleted and need to be replaced. Such battery replacements require an operation, hospital stay and the risk of introducing infection. The high electrical energy that has been used to treat dystonia means that batteries are typically replaced every year or two.

The artificial electrical signals of deep brain stimulation are delivered with three parameters; frequency (Hertz - Hz), voltage (volts) and pulse width (microseconds). It has recently been reported that lower frequency stimulation, at 60Hz rather than 130Hz, can be used effectively to treat dystonia. Such 60Hz stimulation may be more effective for some patients than others. The lower energy demands of 60Hz stimulation would also greatly improve battery life (potentially doubling battery life).

The aim of this study is to assess if 60Hz stimulation is more effective in ameliorating the dystonia of patients who have responded poorly to 130Hz pallidal stimulation. The current status of the evidence is one of clinical equipoise (uncertainty) and therefore suits a double blinded randomised trial.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00971854
Study type	Interventional
Source	University of Oxford
Contact	Wesley Thevathasan, MBBS FRACP
Phone	07748729186
Email	wesley.thevathasan@nds.ox.ac.uk
Status	Recruiting
Phase	N/A
Start date	September 2009
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01433757` - Ampicillin for DYT-1 Dystonia Motor Symptoms	Phase 1
Enrolling by invitation	`NCT00355927` - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.	N/A
Completed	`NCT00169338` - Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia	Phase 2
Completed	`NCT00004421` - Deep Brain Stimulation in Treating Patients With Dystonia	Phase 2/Phase 3
Terminated	`NCT03270189` - Effect of the Visual Information Change in Functional Dystonia	N/A
Recruiting	`NCT02583074` - Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia	N/A
Recruiting	`NCT06117020` - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals	Phase 1
Completed	`NCT01432899` - Studying Childhood-Onset Hemidystonia
Completed	`NCT04948684` - Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Completed	`NCT05106816` - The Effects of Vibrotactile Stimulation in Patients With Movement Disorders	N/A
Recruiting	`NCT05027997` - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm	Phase 2
Completed	`NCT00465790` - Research of Biomarkers in Parkinson Disease	Phase 0
Active, not recruiting	`NCT00142259` - Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia	Phase 4
Recruiting	`NCT05663840` - Effects of Exercise on Dystonia Pathophysiology	N/A
Not yet recruiting	`NCT06038097` - Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia	N/A
Recruiting	`NCT04286308` - Cortical-Basal Ganglia Speech Networks	N/A
Active, not recruiting	`NCT03582891` - The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy	N/A
Completed	`NCT03318120` - Exercise Training in Dystonia	N/A
Completed	`NCT04568681` - Deep Brain Stimulation Effects in Dystonia
Active, not recruiting	`NCT05956223` - The Development of a System for Measurement of Tremor	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.